Visen Pharmaceuticals
Shanghai
About Visen Pharmaceuticals
VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients’ need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases. VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. We have also launched our Greater China R&D and manufacturing site in Suzhou to enhance R&D, manufacturing and commercialization efforts. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $190.0M
- Funding stage: IPO
- Last round: Series B (Jan 2021)
- Ticker: hkg:2561
- Website: visenpharma.com
- Phone: +86 021 5299 9605
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/visen-pharmaceuticals-117927 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.